



## **AgiOS to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021**

January 5, 2021

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.

A live webcast of the presentation and breakout session can be accessed under "Events & Presentations" in the Investors section of the company's website at [www.agios.com](http://www.agios.com). A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

### **About Agios**

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at [www.agios.com](http://www.agios.com).

### **Contacts**

#### **Investors:**

Holly Manning, 617-844-6630  
Director, Investor Relations  
[Holly.Manning@agios.com](mailto:Holly.Manning@agios.com)

#### **Media:**

Jessica Rennekamp, 857-209-3286  
Associate Director, Corporate Communications  
[Jessica.Rennekamp@agios.com](mailto:Jessica.Rennekamp@agios.com)



Source: Agios Pharmaceuticals, Inc.